A large Australian study indicates that atypical depression is a distinct subtype with poorer response to SSRIs and SNRIs, suggesting potential implications for prescribing strategies in this population.
Post hoc analyses of the Phase 3 centanafadine trial for adult ADHD demonstrate improvements in executive function and emotional dysregulation, providing additional efficacy data for this non-stimulant treatment option.
Poster data from the 2026 ASCP Annual Meeting presents Phase 3 trial results for COMP360 psilocybin in treatment-resistant depression, offering early evidence on the efficacy of this novel psychedelic therapy.
A new clinical trial demonstrates promising results for psilocybin in treating recurrent depression in patients who have not failed standard treatments, expanding the potential use case beyond refractory cases.
This case report describes the successful use of valproic acid to treat anxiety-related prolonged mechanical ventilation weaning in a patient with Guillain-Barre syndrome, suggesting a potential off-label utility for valproate in acute anxiety management.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Apr 23 – May 29)
- Monitor for reversible cerebral vasoconstriction syndrome (RCVS) in patients initiating sertraline, as this rare but serious neurological adverse event requires prompt recognition.
- Consider deprescribing stimulants in adult ADHD using the new clinical guidance to manage long-term pharmacotherapy and facilitate discontinuation strategies.
- Anticipate that patients with atypical depression may exhibit poorer response to SSRIs and SNRIs, potentially warranting alternative first-line pharmacological strategies.
- Leverage post hoc data from the centanafadine trial to support its use for improving executive function and emotional dysregulation in adult ADHD beyond core symptom reduction.
- Exercise caution when interpreting psilocybin trial results, as recent evidence like the EPISODE trial shows only modest effects and raises methodological concerns for treatment-resistant depression.
- Explore the synergistic potential of combining intermittent ketamine with neuromodulation to enhance antidepressant treatment response in difficult-to-treat depression.
- Avoid relying on FAAH inhibitors for PTSD treatment at this time, as current Phase II trials have demonstrated no clinical benefit for this indication despite modest efficacy in cannabis use disorder.
- Reassess the risk-benefit profile of stimulant prescribing in ADHD by reviewing updated clinical context to ensure informed decision-making for long-term management.
- Consider valproic acid as a potential off-label option for acute anxiety management, particularly in complex cases involving prolonged mechanical ventilation weaning.
- Expand the potential use case for psilocybin in recurrent depression to include patients who have not yet failed standard treatments, rather than limiting it strictly to refractory cases.
Diagnosis & Treatment 3
An anti-inflammatory drug for rheumatoid arthritis showed early promise in easing symptoms of hard-to-treat depression in a small clinical trial, highlighting a potential immune-targeted treatment avenue.
A clinical trial investigating the clinical efficacy and EEG-based prediction of high-dose versus conventional home-transcranial direct current stimulation (tDCS) for major depressive disorder.
First guidance on deprescribing stimulants in adult ADHD provides clinical direction for managing long-term pharmacotherapy and potential discontinuation strategies.
Drug Development 2
A clinical trial is recruiting to evaluate the efficacy of psilocybin therapy for treating depression in patients with Parkinson's disease.
This review evaluates the pharmacological strategy of inhibiting fatty acid amide hydrolase (FAAH) to enhance anandamide signaling for treating psychiatric disorders, noting that current Phase II trials for FAAH inhibitors have shown modest efficacy in cannabis use disorder but no benefit in PTSD.
Clinical Pearl 2
The EPISODE trial for psilocybin-assisted therapy in treatment-resistant depression shows only modest effects and raises methodological concerns, challenging the current evidence base for this psychedelic intervention.
This case report describes reversible cerebral vasoconstriction syndrome (RCVS) in a patient taking sertraline, highlighting a rare but serious neurological adverse event associated with this SSRI that clinicians should monitor for.
Digital Health 1
A clinical trial investigating the efficacy and safety of Transcranial Temporal Interference Stimulation for Major Depressive Disorder.
Journal Article 1
This article title suggests a comparative analysis of bupropion versus SSRIs in antidepressant-naive, obese patients with major depressive disorder, though the provided text lacks specific clinical findings or outcomes.